RxDoctor Payments DataLook up a doctor →

Annie Im, MD

Internal Medicine · Pittsburgh, PANPI 1760675011

Payments from drug & device makers

$1,197,576in general payments, 2019–2025

Across 382 payments — averaging $3135.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$547K
  • Sanofi US Services Inc.$232K
  • Taiho Oncology, Inc.$163K
  • Novartis$57K
  • Syndax Pharmaceuticals, Inc.$54K
  • Deciphera Pharmaceuticals Inc.$30K
  • plus $116K from 14 others

What the payments were for

  • Consulting fees$36,67189%
  • Travel & lodging$1,9905%
  • Food & beverage$2,2976%
  • Education$1130%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,197,576 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$39,394
Medicare patients
66
Services billed
356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RezurockBelumosudil Mesylate29$516,140
JakafiRuxolitinib Phosphate27$470,577
TibsovoIvosidenib11$349,415
OnuregAzacitidine12$310,074
VenclextaVenetoclax23$86,685
Imatinib Mesylate12$37,447
Voriconazole12$2,890
Acyclovir96$2,474
Fluconazole37$1,361
Pantoprazole Sodium28$861
Hydrocortisone21$659
Potassium Chloride29$461
Levofloxacin28$444
Dexamethasone18$394
Prochlorperazine Maleate12$323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCRezurock$21,904$516,14029 claims
Incyte CorporationJakafi$546,509$470,57727 claims
Servier Pharmaceuticals LLCTibsovo$22$349,41511 claims
E.r. Squibb & Sons, L.L.C.Onureg$26,772$310,07412 claims
AbbVieVenclexta$1,500$86,68523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →